PACB — Pacific Biosciences of California

Pacific Biosciences of California (PACB) is a medical devices company listed on NASDAQ. It is led by Christian O. Henry M.B.A., based in 1305 O?Brien Drive, Menlo Park, CA, United States, 94025, with about 575 employees. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.

Use this PACB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PACB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PACB SEC filings page. Lician reads the product cache first so this HTML stays unique to Pacific Biosciences of California even when a live quote feed is slow.